Characteristics and screening history of women diagnosed with cervical cancer aged 20–29 years

A Castanon *,1, V M W Leung 1, R Landy 1, A W W Lim 1 and P Sasieni 1

1Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK

Background: There was concern that failure to screen women aged 20–24 years would increase the number of cancers or advanced cancers in women aged 20–29 years. We describe the characteristics of women diagnosed with cervical cancer in England aged 20–29 years and examine the association between the period of diagnosis, screening history and FIGO stage.

Methods: We used data on 1800 women diagnosed with cervical cancer between April 2007 and March 2012 at age 20–29 from the National Audit of Invasive Cervical Cancers.

Results: The majority of cancers (995, or 62% of those with known stage) were stage 1A. Cancer at age 20–24 years was rare (12% of those aged 20–29 years), when compared with age 25 (24%) and age 26–29 years (63%); however, cancers in women aged 20–24 years tended to be more advanced and were more often of a rare histological type. For 59% of women under age 30, the cervical cancer was screen detected, most of them (61%) as a result of their first screening test. A three-fold increase in the number of cancers diagnosed at age 25 years was seen since the start of the study period.

Conclusion: Cervical cancer at age 20–24 years is rare. Most cancers in women under age 30 years are screen detected as microinvasive cancer.

There is increasing evidence that cervical screening in women aged 20–24 years is not as effective in preventing cervical cancer as screening women aged 25+ years (Sasieni et al., 2003, 2009). Therefore, in late 2003, a change in cervical screening policy was announced whereby women in England would first be invited at their 25th birthday instead of from age 20 years. There was concern among some that the change in policy would lead to an increase in cervical cancer and in particular to an increase in cancers diagnosed at more advanced stages (Herbert et al., 2008; Fiander, 2008).

The new policy was rolled out in 2004, but was not retrospective in that women already invited for screening before age 25 years would receive a second invitation 3 years later even if still under age 25 years. In addition, it took ~15 months to roll out the change in policy nationally. It was only from mid 2009 that substantial numbers of women would have received a first invitation. In late 2008, there were concerns that the cervical screening programme was not reaching women aged 20–24 years (Foley et al., 2010). There was concern that this may have delayed the diagnosis of cervical cancer and may have led to a change in the incidence of cervical cancer.

With the introduction of the cervical screening programme in 1988 it was hoped that cervical cancer could be almost eliminated, particularly in young women. In fact, the introduction of screening has not only prevented cancers but has also led to those cancers in screened women that are not prevented being diagnosed at much earlier stages. Because the lead time between the onset of early-stage occult cervical cancer and the development of symptoms can be considerable, screening has led to a shift in the peak incidence of cervical cancer (among women eligible for screening) from age 35–49 years in 1993–1995 to age 25–34 years in 2007–2009 (Cancer Research UK, 2010). In addition, cancer rates have steadily been increasing over the past 20 years in young women (Foley et al., 2011), possibly because of changes in the underlying rates of sexually transmitted infections including human papilloma virus (PHLS Communicable Disease Surveillance Centre, 2006a,b; Sargent et al., 2008).

*Correspondence: Dr A Castanon; E-mail: a.castanon@qmul.ac.uk

Received 12 April 2013; revised 4 June 2013; accepted 4 June 2013; published online 2 July 2013

© 2013 Cancer Research UK. All rights reserved 0007 – 0920/13

www.bjcancer.com | DOI:10.1038/bjc.2013.322

35
Cervical cancer in women aged 20–29 years

In addition, the change in policy (from first inviting women at age 20 to age 25 years) occurred over a 15-month period, and hence it is not possible to determine whether women born between 26 August 1984 and 3 November 1985 were invited for screening from age 20 years or not. To assess the impact of the change in policy, we have divided the data set into three time periods of 20 months each. The first period (‘mostly invited from 20’) includes those diagnosed from April 2007 to November 2008; during this period, all women diagnosed at age 25–29 years would have been invited for screening at age 20 years. The middle period (‘mixed’) runs from December 2008 to July 2010; in this period, some of those women diagnosed aged 25 years were first invited at age 20 and some at 25 years. The final period (‘mostly invited from 25’) runs from August 2010 to March 2012, when almost all women diagnosed aged 25 years would have been first invited for screening at age 25 years. Note that none of the women diagnosed aged 20–21 years in this study were invited for screening before diagnosis, and all of those diagnosed at age 27–29 years should have been invited at age 20 years.

Delays in the registration of newly diagnosed cancers in our audit mean that the number of cases will be underreported, particularly in the most recent period. To adjust for this we have inflated the rates (but not the numbers) in the last period (August 2010 to March 2012). The inflation factor (13.9%) is the proportion by which the number of cases aged 20–29 years diagnosed between August 2008 and March 2010 increased between the 2010 and the 2012 data sets. The inflation factor is generous and there is evidence that reporting into the audit is becoming timelier; over the period August 2009 to March 2011, the increase between the 2011 data set and the 2012 data set was 8.7% compared with 11.1% for the corresponding periods a year earlier.

We have classified the pathway to diagnosis for these women according to their screening history as follows (full details can be found in Appendix 1):

1. Never screened or lapsed: women with no screening history (more than 14 days before diagnosis) other than possibly a single inadequate test; women (N = 23) whose last test resulted in routine recall and was over 3.5 years before diagnosis (the group labelled ‘lapsed’ in Appendix 1).

2. Screen detected prevalent (on first test): women diagnosed within 4 months of cytology indicating referral to colposcopy. In addition, there should be no prior test resulting in routine recall, and if the first screening test resulted in early recall, the next test must be within 1 year.

3. Screen detected incident: diagnosed between 2.75 and 3.5 years after a negative test. The interval following an early recall test (if any) must not exceed 1 year and they must have a cytology test indicating referral to colposcopy within 4 months of diagnosis.

4. Screen detected lapsed: diagnosed > 3.5 years after a negative test. Same definition as (3) above, but the women have a negative test > 3.5 years before the abnormal test.

5. Post abnormal: The interval following early recall tests (if any) exceeds 1 year and/or they are diagnosed more than 4 months after a cytology indicating referral to colposcopy or they have no suspends but they have a history of low-grade cytology resulting in early recall.

6. Interval cancers: women diagnosed <2.75 years after a cytology test resulting in routine recall. Also includes women diagnosed between 2.75 and 3.5 years after a cytology test resulting in routine recall, but with no other tests before diagnosis, or women with their first early recall on the pathway to diagnosis 2.75–3.5 years after a cytology test resulting in routine recall, with no more than a year between an early recall and the following test or diagnosis.

**MATERIALS AND METHODS**

**Subjects.** We used data on women in England diagnosed with cervical cancer (ICD-10 C53) aged 20–29.99 years between April 2007 and March 2012 from the National Audit of Invasive Cervical Cancers (October 2012 data set). The audit includes over 90% of all cancers diagnosed nationally. The screening histories of these women were abstracted from routinely recorded cervical cytology records held on the National Cervical Screening Call/Recall System, including all NHS and many private tests. Treatment details, FIGO stage at diagnosis and histological type are recorded as and when the data become available. As these data are collected from multiple sources, they are not as complete or accurate as the details, FIGO stage at diagnosis and histological type are recorded previously (Sasieni et al, 2003, 2009).

**Statistical methods.** Descriptive statistics were examined to compare the distributions of the International Federation of Gynaecology and Obstetrics (FIGO) staging system at diagnosis, histology, treatment and socioeconomic status, and to examine changes in screening history by stage.

Delays in the registration of newly diagnosed cancers in our audit mean that the number of cases will be underreported, particularly in the most recent period. To adjust for this we have inflated the rates (but not the numbers) in the last period (August 2010 to March 2012). The inflation factor (13.9%) is the proportion by which the number of cases aged 20–29 years diagnosed between August 2008 and March 2010 increased between the 2010 and the 2012 data sets. The inflation factor is generous and there is evidence that reporting into the audit is becoming timelier; over the period August 2009 to March 2011, the increase between the 2011 data set and the 2012 data set was 8.7% compared with 11.1% for the corresponding periods a year earlier.

We have classified the pathway to diagnosis for these women according to their screening history as follows (full details can be found in Appendix 1):

1. Never screened or lapsed: women with no screening history (more than 14 days before diagnosis) other than possibly a single inadequate test; women (N = 23) whose last test resulted in routine recall and was over 3.5 years before diagnosis (the group labelled ‘lapsed’ in Appendix 1).

2. Screen detected prevalent (on first test): women diagnosed within 4 months of cytology indicating referral to colposcopy. In addition, there should be no prior test resulting in routine recall, and if the first screening test resulted in early recall, the next test must be within 1 year.

3. Screen detected incident: diagnosed between 2.75 and 3.5 years after a negative test. The interval following an early recall test (if any) must not exceed 1 year and they must have a cytology test indicating referral to colposcopy within 4 months of diagnosis.

4. Screen detected lapsed: diagnosed > 3.5 years after a negative test. Same definition as (3) above, but the women have a negative test > 3.5 years before the abnormal test.

5. Post abnormal: The interval following early recall tests (if any) exceeds 1 year and/or they are diagnosed more than 4 months after a cytology indicating referral to colposcopy or they have no suspends but they have a history of low-grade cytology resulting in early recall.

6. Interval cancers: women diagnosed <2.75 years after a cytology test resulting in routine recall. Also includes women diagnosed between 2.75 and 3.5 years after a cytology test resulting in routine recall, but with no other tests before diagnosis, or women with their first early recall on the pathway to diagnosis 2.75–3.5 years after a cytology test resulting in routine recall, with no more than a year between an early recall and the following test or diagnosis.
RESULTS

The study includes a total of 1800 women diagnosed with cervical cancer aged 20–29 years between April 2007 and March 2012. The majority of cancers (63.2%) were diagnosed between the age of 26 and 29 years, with a further 24.4% diagnosed at age 25 years. Cervical cancer is rare in women aged 20–24 years compared with women aged 25–29 years, with only 12.4% (n = 223) of cancers diagnosed in this age group, which is roughly equivalent to the number of cancers diagnosed at age 26 years (n = 257). Furthermore, half (n = 110) of all cancers diagnosed at age 20–24 years were diagnosed at age 24 years, 25% (n = 56) at age 23 years and 26% (n = 57) at age 20–22 years.

Table 1 shows the characteristics of these women by age at diagnosis. Over 60% of cancers in this age group are diagnosed as stage 1A cancer and, across all stages, 69% are treated conservatively with fertility-sparing treatment (the proportion increases to 94% among those with stage 1A cancer and known treatment). Cancers in women aged 20–24 years tend to be more advanced at diagnosis than those in older women: a higher proportion of women under age 25 years had stage 2 or worse cancer (20% vs 6%, P < 0.001), resulting in more women treated by chemotherapy and/or radiotherapy ± hysterectomy (37% vs 14%, P < 0.001) and a smaller proportion having fertility-sparing treatment (46% vs 72%, P < 0.001); a higher proportion were diagnosed with adenosquamous carcinoma and other rarer histological types (10% vs 4%, P < 0.001). No differences in socioeconomic status were observed.

Table 1. Characteristics of women diagnosed with cervical cancer aged 20–29 years

|                     | Age 20-24 | Age 25 | Age 26–29 | All ages |
|---------------------|-----------|--------|-----------|----------|
| **Stage**           |           |        |           |          |
| 1A                  | 77        | 40.7%  | 293       | 74.9%    | 625      | 60.4%    | 995      | 61.6%    |
| 1B                  | 74        | 39.2%  | 83        | 21.2%    | 333      | 32.2%    | 490      | 30.3%    |
| 2+                  | 38        | 20.1%  | 15        | 3.8%     | 77       | 7.4%     | 130      | 8.0%     |
| Unknown             | 34        |        | 49        |          | 102      |          | 185      |          |
| **Histology**       |           |        |           |          |
| Squamous            | 163       | 75.5%  | 352       | 82.8%    | 863      | 79.0%    | 1378     | 79.5%    |
| Adenocarcinoma      | 32        | 14.8%  | 55        | 12.9%    | 186      | 17.0%    | 273      | 15.8%    |
| Adenosquamous       | 9         | 4.2%   | 9         | 2.1%     | 28       | 2.6%     | 46       | 2.7%     |
| Other               | 12        | 5.9%   | 9         | 2.1%     | 15       | 1.4%     | 36       | 2.1%     |
| Unknown             | 7         |        | 15        |          | 45       |          | 67       |          |
| **Treatment**       |           |        |           |          |
| Cone biopsy or trachelectomy | 71 | 45.8% | 227 | 80.5% | 560 | 69.1% | 858 | 68.8% |
| Hysterectomy (simple or radical) | 26 | 16.8% | 26 | 9.2% | 131 | 16.2% | 183 | 14.7% |
| Chemotherapy and/or radiotherapy ± hysterectomy | 58 | 37.4% | 29 | 10.3% | 119 | 14.7% | 206 | 16.5% |
| Unknown             | 68        |        | 158       |          | 327      |          | 553      |          |
| **Period of diagnosis** |       |        |           |          |
| Diagnosed between April 2007 and November 2008 | 89 | 39.9% | 68 | 15.5% | 367 | 32.3% | 524 | 29.1% |
| Diagnosed between December 2008 and July 2010 | 77 | 34.5% | 146 | 33.2% | 455 | 40.0% | 678 | 37.7% |
| Diagnosed between August 2010 and March 2012 | 57 | 25.6% | 226 | 51.4% | 315 | 27.7% | 598 | 33.2% |
| **Deprivation (in deciles)** |       |        |           |          |
| 0–2, most deprived 30% | 73 | 42.9% | 153 | 42.4% | 361 | 40.7% | 587 | 41.4% |
| 3–5                 | 56        | 32.9%  | 101       | 28.0%    | 274      | 30.9%    | 431      | 30.4%    |
| 6–9, least deprived 40% | 41 | 24.1% | 107 | 29.6% | 252 | 28.4% | 400 | 28.2% |
| Unknown             | 53        |        | 79        |          | 250      |          | 382      |          |
| **Screening history** |       |        |           |          |
| Never               | 97        | 43.5%  | 38        | 8.6%     | 86       | 7.6%     | 221      | 12.3%    |
| Interval            | 7         | 3.1%   | 13        | 3.0%     | 101      | 8.9%     | 121      | 6.7%     |
| Screen detected     |           |        |           |          |
| Prevalent (on first test) | 72 | 32.3% | 290 | 65.9% | 277 | 24.4% | 639 | 35.5% |
| Incident (2.75–3.5 years after negative) | 10 | 4.5% | 5 | 1.1% | 163 | 14.3% | 178 | 9.9% |
| Lapsed (> 3.5 years after negative) | 6 | 2.7% | 30 | 6.8% | 199 | 17.5% | 235 | 13.1% |
| **Post abnormal**   |           |        |           |          |
| Time from abnormal to diagnosis <1 year | 18 | 8.1% | 55 | 12.5% | 152 | 13.4% | 225 | 12.5% |
| Time from abnormal to diagnosis ≥1 year | 13 | 5.8% | 9 | 2.0% | 159 | 14.0% | 181 | 10.1% |
| Total N             | 223       | 100%   | 440       | 100%     | 1137     | 100%     | 1800     | 100%     |
between the age groups ($P = 0.434$), but overall women in this study were more deprived when compared with the national distribution.

Overall, 29% (524) of cancers were diagnosed between April 2007 and November 2008, 38% (678) between December 2008 and July 2010 and the remaining 33% (598) were diagnosed from August 2010 to March 2012. The increase in cancers diagnosed in the middle period is probably because of a large number of women attending screening as a result of the much publicised death from cervical cancer of celebrity Jade Goody in March 2009. The increase in cervical cancer in England in 2009, particularly in women aged 25–39 years, has been noted before (Sasieni and Castanon, 2012).

The age distribution at which women are diagnosed with cervical cancer has changed considerably during the study period. Although the proportion diagnosed at age 20–24 years is currently close to half of what it was at the start of the study (17% in the first period vs 10% in the last period), the proportion diagnosed at age 25 years has increased almost three-fold (from 13% to 38%). In the first period, most women aged 20–29 years were first invited for screening at age 20 years and the number and rate of cervical cancers increased with increasing age (Figure 1A). The age at diagnosis begins to change in the period between December 2008 and July 2010, and there is a noticeable increase in the number and rate of cancers among those aged 25–29 years (Figure 1B). From August 2010 onwards (Figure 1C), when almost all women diagnosed under age 26 years would not have been invited for screening until age 25 years, we see a substantial increase in diagnoses at age 25 years (despite the potential for undercounting because of delays in registration) with a fall in numbers of cancers diagnosed at age 26–29 years. In fact, the rate at age 25 years increases to 41.5 per 100 000 (the highest observed during the study period), and between 25.0 and 25.25 the rate peaks at 64.6 per 100 000 woman-years. It is also seen that the fall in diagnosed women aged 26–29 years looks to be real in that there is a fall in the rates even after adjusting for the effect of delayed registration. An increase is also observed in women diagnosed between age 24.75 and 25 years because of women who attended and were diagnosed promptly after their first invitation for screening, which is sent out up to 6 months before their 25th birthday. It is not yet possible to observe the effect of changing the age of first invitation on women diagnosed at age 26–29 years because over 75% were invited for screening at age 20 years.

The effect of the change in screening policy can be seen in the differences in screening history between the age groups (Table 1). Almost half of women diagnosed at age 20–24 years had never been screened before (47%), and there was a noticeable decrease in the proportion screened before age 25 years (from 71% in the first period to 53% in the last period). In contrast, the proportion screened after age 25 years increased from 11% to 26% over the same period.

Table 2. International Federation of Gynaecology and Obstetrics (FIGO) stage by age and date of diagnosis

| Age at diagnosis, years | Period of diagnosis | 1A | % | 1B+ | % | Unknown | % | Total | % |
|------------------------|--------------------|----|---|-----|---|---------|---|-------|---|
| 20–24                  | Apr 2007–Nov 2008  | 37 | 42%| 42  | 47%| 10      | 11%| 89    | 100%|
|                        | Dec 2008–Jul 2010  | 26 | 34%| 43  | 56%| 8       | 10%| 77    | 100%|
|                        | Aug 2010–Mar 2012  | 14 | 25%| 34  | 60%| 9       | 16%| 57    | 100%|
| 25                     | Apr 2007–Nov 2008  | 41 | 60%| 19  | 28%| 8       | 12%| 68    | 100%|
|                        | Dec 2008–Jul 2010  | 94 | 64%| 40  | 27%| 12      | 8% | 146   | 100%|
|                        | Aug 2010–Mar 2012  | 158| 70%| 52  | 23%| 16      | 7% | 226   | 100%|
| 26–29                  | Apr 2007–Nov 2008  | 194| 53%| 141 | 38%| 32      | 9% | 367   | 100%|
|                        | Dec 2008–Jul 2010  | 255| 56%| 178 | 39%| 22      | 5% | 455   | 100%|
|                        | Aug 2010–Mar 2012  | 176| 56%| 119 | 38%| 20      | 6% | 315   | 100%|

Figure 1. Rate and number of cancers in the study by age at diagnosis. (A) For those diagnosed between April 2007 and November 2008, (B) for those diagnosed between December 2008 and July 2010, (C) for those diagnosed between August 2010 and March 2012. The darker shading indicates cancers diagnosed at age 25.

Table 2. International Federation of Gynaecology and Obstetrics (FIGO) stage by age and date of diagnosis
been screened (44%) compared with 9% of those aged 25 years and 8% of those aged 26–29 years. Women aged 25 years at diagnosis were most likely to have been screen detected on their first test (66%).

The distribution of FIGO stage at diagnosis in each period is reported in Table 2. An increase in the proportion of stage 1B or worse cancers diagnosed at age 20–24 years is seen between the first study period and the last, whereas a decrease in stage 1B + cancers is observed in women aged 25 years and no change in the stage distribution is observed for women aged 26–29 years. Changes in the screening histories over the study period are related to the observed changes in the FIGO stage at diagnosis in these young women.

Screening histories by FIGO stage are presented in Table 3. Women who were not screened before diagnosis and those with interval cancers were far more likely to be diagnosed with advanced-stage cancer: 30% of 280 cancers (with known stage) were stage 2 or worse compared with 3% of 1335 that were in some sense screen detected (i.e., all the other groups). The unscreened and interval cases were also far less likely to have stage 1A cancer (20% of 280 cancers were known to be stage 1A) than the other cases (70% of 1335 cancers).

This is the largest study of women diagnosed with cervical cancer under the age of 30 years. It includes over 90% of all cancers at age 20–29 years in England and has complete screening histories. However, it will not be possible to study the full impact of the change in policy on rates of cervical cancer until the first cohort of women invited for screening at age 25 years reach the age of 30 years (around 2015). We cannot disentangle changes in underlying risk factors from changes in the screening policy, both of which are confounded by the Jade Goody effect. Nevertheless, by dividing the study period in three we have been able to show the impact of the change in policy on the age at which cancer is diagnosed.

A weakness of this study is that delays in reporting newly diagnosed cases to the audit mean that the numbers in the most recent period will be underreported. We have taken the view that the timeliness of the data justifies publication even though it is likely to be incomplete. Certainly, the increase in cancers diagnosed at age 25 years (despite the likelihood of underreporting) seems to justify such a decision. We have attempted to adjust the rates taking into account the historical impact of delayed registration.

There are three possible explanations for the increase in cancers observed at age 25 years: (1) cancers are being diagnosed later, that is, cancers that would have been screen detected at age 20–24 years are now diagnosed as stage 1A cancers at age 25 years; (2) cancers are not being prevented, that is, women who would have been treated for CIN2/3 at age 20–24 years are now being diagnosed with cancer at age 25 years; (3) cancers are being diagnosed earlier, that is, women who would have been diagnosed with cancer at age 26 or 27 years on their third round of screening are now being diagnosed at age 25 years on their first screening test. It is not possible to say which of these scenarios has played the most prominent role, but our results show no evidence of an increase in 1B or worse cervical cancer at age 25 years. Whatever the underlying reasons for the observed changes, results show that 62% of women invited for screening at age 20–29 years were diagnosed as stage 1A cancers at age 25 years; (2) cancers are not being prevented, that is, women who would have been treated for CIN2/3 at age 20–24 years are now being diagnosed with cancer at age 25 years; (3) cancers are being diagnosed earlier, that is, women who would have been diagnosed with cancer at age 26 or 27 years on their third round of screening are now being diagnosed at age 25 years on their first screening test. It is not possible to say which of these scenarios has played the most prominent role, but our results show no evidence of an increase in 1B or worse cervical cancer at age 25 years. Whatever the underlying reasons for the observed changes, results show that 62% of women invited for screening at age 20–29 years were diagnosed as stage 1A cancers at age 25 years; of these 94% (of those with known stage) were treated with Large loop excision of the transformation zone (LLETZ) or Cone biopsy only. These cases should be considered successes of the programme because they not only have excellent survival (98% 5-year survival; Kosary, 2007) but also the treatment is essentially the same as would be recommended for women with high-grade cervical intraepithelial neoplasia.

We are unable to distinguish cytology tests taken in response to symptoms from those following an invitation for screening.

### Table 3. Screening history (at least 14 days before diagnosis) by the International Federation of Gynaecology and Obstetrics (FIGO) stage among those with known stage

|                     | Stage 1A | Stage 1B | Stage 2 + | Cases with known stage | Cases with stage unknown |
|---------------------|---------|---------|-----------|------------------------|--------------------------|
| Never               | 35      | 20%     | 83        | 48%                    | 55                       |
| Interval            | 22      | 21%     | 56        | 52%                    | 29                       |
| Subtotal            |         |         | 139       | 50%                    |                          |
| Screen detected     |         |         |           |                        |                          |
| Prevalent (on first test) | 422   | 72%     | 150       | 25%                    | 18                       | 3%                       | 590                       | 100%                      | 49/639 | 8% |
| Incident (2.75–3.5 years after negative) | 121   | 72%     | 42        | 25%                    | 4                        | 2%                       | 167                       | 100%                      | 11/178 | 6% |
| Lapsed (>3.5 years after negative) | 155   | 71%     | 58        | 27%                    | 5                        | 2%                       | 218                       | 100%                      | 17/235 | 7% |
| Subtotal            | 698     | 72%     | 250       | 26%                    | 27                       | 3%                       | 975                       | 100%                      | 77/1052 | 7% |
| Post abnormal       |         |         |           |                        |                          |
| Time from abnormal to diagnosis <1 year | 145   | 70%     | 57        | 27%                    | 6                        | 3%                       | 208                       | 100%                      | 17/225 | 8% |
| Time from abnormal to diagnosis >1 year | 95    | 63%     | 44        | 29%                    | 13                       | 9%                       | 152                       | 100%                      | 29/181 | 8% |
| Sub-total           | 240     | 67%     | 101       | 28%                    | 19                       | 5%                       | 360                       | 100%                      | 46/406 | 11% |
| Total               | 995     | 62%     | 490       | 30%                    | 130                      | 8%                       | 1615                      | 100%                      | 185/1800 | 10% |
However, the large proportion of advanced stage cancers among women never screened and interval cancers suggest that our screening classification successfully identified those who are most likely to have had symptoms. Nevertheless, women who had cytology taken in response to symptoms may have been included in any of the other categories if the sample was taken more than 14 days before diagnosis.

Studies of cervical cancer in women aged 20–29 in the United Kingdom are few and tend to be small (Rieck et al, 2006; Nair et al, 2007; Herbert et al, 2008; Patel et al, 2012). The combined results for all but the largest study include a total of just 18 cancers (all of which were in women offered screening from age 20 years) diagnosed at age 20–24 years. Over 60% of cancers in these studies were stage I A and roughly the same proportions were found to be screen detected. The largest study by Patel et al (2012) included 152 cases aged 20–29 years diagnosed over a 10-year period in the north east (NE) of England. They found a much higher proportion of cancers at age 20–24 years (26%) than found in this national study (12%). In 2010, cancers diagnosed at age 20–24 years accounted for just 2% of all cervical cancers diagnosed in England (Office for National Statistics, 2012).

Patel et al (2012) compared incidence rates between 2000–2002 and 2007–2009 in NE England and concluded there has been an increase in diagnoses of cancer in women under the age of 30 years. However, results were similar for Wales where they continue to screen from age 20 years. The authors concluded that rather than the change in policy, high rates of sexually transmitted infections (STIs) and other underlying risk factors affecting the population of the NE of England are responsible for the increased rates of cervical cancer. This, in addition to the fact that most women in the study of Patel et al (2012) were invited for screening from age 20 years, may account for the differences (described above) in the proportion of women diagnosed at age 20–24 years between studies.

Similarly, Foley et al (2011) reported increasing rates of cervical cancer in England in women under age 40 years, with those born from 1972 onwards at greater risk. Incidence rates since 1975 show rates in women aged 20–24 years of ~ 2.1 per 100,000 women from 1975 up until 1999. Between 2000 and 2004, the average rate jumped to 3.0 and it has remained the same in the following 5-year period. Rates in women aged 25–29 years are harder to interpret; during the 1980s, the average rate was 1.3 per 100,000 women, between 1990 and 2004 it was 9.6 per 100,000, and it then jumped to 15.8 per 100,000 between 2005 and 2009 (Office for National Statistics, 1975-2010). The increase of cervical cancer in women born since 1972 is most likely because of an increase in the underlying risk factors for cervical cancer (rates of STIs, smoking). These trends are concerning, and efforts should be focussed on increasing coverage among women aged 25–29 years rather than on reintroducing screening among those aged 20–24 years. Longer-term HPV vaccination should greatly reduce cervical cancer rates in those born since 1994.

There was concern (Fiander, 2008) that inviting women at age 25 years would lead to a drop in coverage in those under age 30 years. Latest statistics show that 3-yearly coverage in those aged 25–29 years has remained roughly the same (~ 62%) from 2002 to 2012 (screening programme stats 2011/12). Nevertheless, it is low compared with coverage among those aged 30–49 years (71% on average).

Results presented here show that most cancers diagnosed at age 20–29 years are screen detected microinvasive cancer (stage I A) with excellent prognosis. As a result of the change in policy, there has been a shift in the age at which women are diagnosed; since August 2010, half of all cancers in this age group have been diagnosed at age 25 years. Although cancer at age 20–24 years tends to be diagnosed at more advanced stages, it is rare in this age group.

ACKNOWLEDGEMENTS

This work is supported by Cancer Research UK (C8162/10406 and C8162/12537).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ETHICAL APPROVAL

The collection of data as part of this audit has been covered since 2003 by section 251 of the NHS Act 2006 re-enacted Section 60 of the Health and Social Care Act 2001 approval (PIAG 1-08/a/2003). The analysis of anonymised data in this context is considered service evaluation that does not require research ethics approval according to the UK guidelines (NRES) (National Patient Safety Agency, 2009).

DISCLAIMER

The funder had no input in the analysis or interpretation of the data or the writing of the paper. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

REFERENCES

Cancer Research UK (2010) CANCERSTATS: Cervical Cancer - UK incidence statistics. European Age-Standardised Incidence Rates per 100,000 Population, by Age, Females, UK 1993-2009 [Online]. Available: http://www.cancerresearchuk.org/cancer-info/cancerstats/types/cervix/incidence/world/Accessed 05 March 2013.

Department for Communities and Local Government (2011) English Indices of Deprivation 2010: Technical Report England. Available https://www.gov.uk/government/publications/english-indices-of-deprivation-2010-technical-report#http://www.communities.gov.uk/publications/communities/indices/deprivation07.

Department of Health (2010) Clinical practice guidelines for the assessment of young women aged 20-24 with abnormal vaginal bleeding. Available http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_113478.

Fiander AN (2008) Cervical screening in young women aged 20-24 years. J Fam Plann Reprod Health Care 34: 19.

Foley G, Alston R, Geraci M, Brabin L, Kitchener H, Birch J (2011) Increasing rates of cervical cancer in young women in England: an analysis of national data 1982-2006. Br J Cancer 105: 177–184.

Health and Social Care Information Centre. S. A. I (2012) Cervical screening programme England, 2011/12. Available: http://www.cancerscreening.nhs.uk/cervical/statistics-bulletin.html.

Herbert A, Holdsworth G, Kubble AA (2008) Cervical screening: why young women should be encouraged to be screened. J Fam Plann Reprod Health Care 34: 21–25.

Kosary CL (2007) Cancer of the Cervix Uteri. In SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001. Patient and Tumor Characteristics, Ries LAG, Young IJ, Keel GE, Eisner MP, Lin YD, Horner M-J (eds) (National Cancer Institute, SEER Program: Bethesda, MD, NIH Pub No. 07-6215).

Nair MS, Bhandari HM, Nordin AJ (2007) Cervical cancer in women aged less than 25: East Kent experience. J Obstet Gynaecol 27: 706–708.

National Patient Safety Agency (2009) NRES Leaflet: Defining research. [Online]. Available http://www.nres.nhs.uk/applications/is-your-project-research/.

Office for National Statistics (1975-2010) Cancer statistics registrations, England (Series MB1). Dataset prepared by Cancer Research UK: London,
The following table outlines the screening history classification based on time from last suspend to diagnosis and time from last routine test to early recall, suspend or diagnosis, whichever comes first.

**Table A1. Screening history classification**

| Time from last suspend to diagnosis | No early recall | Early recall – gap < 1 year | Early Recall – gap ≥ 1 year |
|------------------------------------|-----------------|----------------------------|----------------------------|
| Time from last routine test to early recall, suspend or diagnosis, whichever comes first | | | |
| None | | | |
| N = 212 | | | |
| Screen detected (SD) on first test | | | |
| N = 614 | | | |
| Post abnormal | | | |
| N = 127 | | | |
| N = 3 | | | |
| SD on first test | | | |
| N = 25 | | | |
| N = 16 | | | |
| N = 9 | | | |
| Post abnormal | | | |
| N = 46 | | | |
| N = 31 | | | |
| Post abnormal | | | |
| N = 9 | | | |
| N = 7 | | | |
| Post abnormal | | | |
| N = 7 | | | |
| N = 6 | | | |
| Post abnormal | | | |
| N = 3 | | | |
| Ongoing | | | |
| N = 176 | | | |
| Interval | | | |
| N = 29 | | | |
| Post abnormal | | | |
| N = 14 | | | |
| N = 8 | | | |
| N = 2 | | | |
| N = 5 | | | |
| Post abnormal | | | |
| N = 7 | | | |
| N = 4 | | | |
| Ongoing | | | |
| N = 27 | | | |
| Interval | | | |
| N = 2 | | | |
| N = 1 | | | |
| N = 0 | | | |
| Post abnormal | | | |
| N = 0 | | | |
| N = 0 | | | |
| N = 0 | | | |
| N = 0 | | | |
| Ongoing | | | |